

Ministry of Health

OHIP, Pharmaceuticals and Devices Division

Drug Submission Status

Report for July 2022

Complete Streamlined Multiple-Source

Submissions for Off-Formulary Interchangeability

The Ministry of Health and Long-Term Care has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via a OPDD Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Mint Pharmaceuticals Inc.	Mint-Frovatriptan	Frova	FROVATRIPTAN SUCCINATE	2.5 mg	tablet	02509687
Sanis Health Inc.	Montelukast	Singulair	MONTELUKAST SODIUM	5mg	chewable tablet	02379325
Nora Pharma	Priva-Tadalafil	Cialis	TADALAFIL	5 mg	tablet	02452480
Nora Pharma	Priva-Tadalafil	Cialis	TADALAFIL	10 mg	tablet	02452499
Nora Pharma	Priva-Tadalafil	Cialis	TADALAFIL	20 mg	tablet	02452502